Novel glucokinase activators: a patent review (2008 – 2010)

Bibliography

• Grimsby J, Sarabu R, Corbett WL, Allosteric activators of glucokinase: potential role in diabetes therapy. Science 2003;301:370-3
   PubMed Web of Science ®Google Scholar
• Sarabu R, Berthel SJ, Kester RF, Tilley JW. Glucokinase activators as new type 2 diabetic therapeutic agents. Expert Opin Ther Pat 2008;18:759-68
   Web of Science ®Google Scholar
• Fyfe MCT, Procter MJ. Glucokinase activators as potential antidiabetic agents possessing superior glucose lowering efficacy. Drugs Future 2009;34:641-53
   Web of Science ®Google Scholar
• Matschinsky F. Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 2009;8:399-417
   PubMed Web of Science ®Google Scholar
• Matschinsky F, Magnuson MA, editors. Glucokinase and glycemic disease. S. Karger AG, Basel; 2004
   Google Scholar
• Pfizer, Inc., USA. Fluorinated heteroaryls. WO2010013161; 2010
   Google Scholar
• Pfizer, Inc., USA. Substitured heteroaryls. US2010063063; 2010
   Google Scholar
• Pfefferkorn JA, Lou J, Minich ML, Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle. Bioorg Med Chem Lett 2009;19:3247-52
   Google Scholar
• Takeda Pharmaceutical Co. Ltd, Japan; Takeda San Diego, Inc. Glucokinase activators. WO2008079787; 2008
   Google Scholar
• Takeda Pharmaceutical Co. Ltd, Japan; Takeda San Diego, Inc. Glucokinase activators. WO2009140624; 2009
   Google Scholar
• Takeda Pharmaceutical Co. Ltd, Japan; Takeda San Diego, Inc. Glucokinase activators. WO2008116107; 2008
   Google Scholar
• pKact –defined as – pKact is negative log of Kact value. Kact is the concentration that displays 50% of the maximal increase in GK activity observed using saturated activator concentration. See Takeda Pharmaceutical Co. Ltd, Japan; Takeda San Diego, Inc. Glucokinase activators. WO20070281942; 2007
   Google Scholar
• F. Hoffmann-La Roche AG, Switz. Pyrrolidinone glucokinase activators. WO2009127546; 2009
   Google Scholar
• F. Hoffmann-La Roche AG, Switz. Pyridazinone glucokinase activators. WO2009127544; 2009
   Google Scholar
• Tanabe Seiyaku Co., Ltd., Japan. Hydrazones. JP20100037337; 2010
   Google Scholar
• Sidduri A, Grimsby JS, Corbett WL, 2,3-Disubstituted acrylamides as potent glucokinase activators. Bioorg Med Chem Lett 2010;20:5673-76
   Google Scholar
• AstraZeneca AB, Sed.; AstraZeneca UK Ltd. Therapeutic agents 414. WO2010015849; 2010
   Google Scholar
• Advinus Therapeutics Private Ltd, India. 2,2,2-Trisubstituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application. WO2008104994; 2008
   Google Scholar
• Advinus Therapeutics Private Ltd, India. Acetamide derivatives as glucokinase activators, their process and pharmaceutical application. WO2009047798; 2009
   Google Scholar
• Merck GmbH, Germany. beta-Aminoacids for treatment of diabetes. WO2009092432; 2009
   Google Scholar
• Takeda Pharmaceutical Co. Ltd, Japan. Nitrogen containing five membered heterocyclic compound. WO2008136428; 2008
   Google Scholar
• Takeda Pharmaceutical Co. Ltd, Japan. Nitrogenated 5-membered heterocyclic compound. WO2009128481; 2009
   Google Scholar
• AstraZeneca AB, Sed.; AstraZeneca UK Ltd. Benzoyl heterocyclyl compounds as glucokinase (GLK) activators. WO200805117; 2008
   Google Scholar
• AstraZeneca AB, Swed.; AstraZeneca UK Ltd. Chemical compounds. WO2008050101; 2008
   Google Scholar
• AstraZeneca AB, Swed.; AstraZeneca UK Ltd. Chemical compounds. WO20100092387; 2010
   Google Scholar
• AstraZeneca AB, Swed.; AstraZeneca UK Ltd. Chemical compounds. WO20100092386; 2010
   Google Scholar
• Banyu Pharmaceutical Co. Ltd, Japan. Method for producing pyrazol-3-yl-benzamide derivative. WO2009041475; 2009
   Google Scholar
• Merck GmbH, Germany. N-(Pyrazol-3-yl)-benzamide derivatives as glucokinase activators. WO2009046802; 2009
   Google Scholar
• Novo Nordisk A/S, Denmark. Benzamide glucokinase activators. WO2007125105; 2007
   Google Scholar
• Merck GmbH, Germany. Pyridine derivatives useful as glucokinase activators. WO2009046784; 2009
   Google Scholar
• a) Array Biopharma Ltd, USA. Glucokinase activators. WO2007117381; 2009. b) 2-Aminopyridine analogs as glucokinase activators. WO2008118718; 2008. c) 2-Aminopyridines as glucokinase activators. WO2008091770; 2008. d) Pyridin-2-yl-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus. WO2009042435; 2009
   Google Scholar
• Merck GmbH, Germany. Carboxamide-heteroaryl derivatives for the treatment of diabetes. WO2009106209; 2009
   Google Scholar
• Banyu Pharmaceutical Co. Ltd, Japan. 2-Pyridine carboxamide derivative having GK-activating activity. WO2008044777; 2008
   Google Scholar
• Merck GmbH, Germany. 5-Oxo-2,3,4,5-tetrahydro-benzo[b]oxapine-4-carboxylic acid amides and 2,3-dihydro-benzo[b]oxapine-4-carboxylic acid amide for treatment and prevention of diabetes type 1 and type 2. WO2009109270; 2009
   Google Scholar
• Novo Nordisk A/S, Denmark. Urea glucokinase activators. WO2008084043; 2008
   Google Scholar
• Novo Nordisk A/S, Denmark. Urea glucokinase activators. WO2008084044; 2008
   Google Scholar
• Takeda Pharmaceutical Co. Ltd, Japan; a) Fused ring compounds and use thereof. WO2009125873; 2009. b) Indole compound. US2008096877; 2008
   Google Scholar
• Takeda Pharmaceutical Co. Ltd, Japan. Fused heterocyclic compound. WO2008047821; 2008
   Google Scholar
• Banyu Pharmaceutical Co. Ltd, Japan. Fused heterocyclic compound. WO2009063821; 2008
   Google Scholar
• Bristol-Myers Squibb Co., USA. Novel glucokinase activators methods of using same. WO2008005914; 2008
   Google Scholar
• Bristol-Myers Squibb Co., USA; a) 1,3-Dihyrdroxy substituted phenylamide glucokinase activators. WO200815463; 2008. b) Novel glucokinase activators and methods of using same. WO2008005964; 2008
   Google Scholar
• Leighton B, Atkinson A, Coghlan MP. Small molecule glucokinase activators as novel anti-diabetic agents. Biochemical Soc Trans 2005;33:371-4
   PubMed Web of Science ®Google Scholar
• Novo Nordisk A/S, Denmark. Use of liver selective glucoskinase activators. US20080026987; 2008
   Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• Tilley JW. Glucokinase activators: Novo Nordisk's WO2008084044 and Array Biopharma's WO2008091770. Expert Opin Ther Pat 2009;19:549-53
   PubMed Web of Science ®Google Scholar
• NovoNordsk Press Release which may be Accessed from: http://www.ttpharma.com/PressReleases/2007/20070220TransTechPharmaInc/tabid/195/Default.aspx
   Google Scholar